| Keywords: |
unclassified drug; clinical trial; angiogenesis inhibitor; nonhuman; positron emission tomography; technetium 99m; radiopharmaceuticals; cell proliferation; monitoring; animal; metabolism; unindexed drug; apoptosis; gene expression; drug design; angiogenesis; neovascularization, pathologic; cancer therapy; hypoxia; iodine 125; drug distribution; drug uptake; radiopharmaceutical agent; scintiscanning; methoxy isobutyl isonitrile technetium tc 99m; binding site; nuclear medicine; radioisotope; drug half life; single photon emission computer tomography; angiogenesis inhibitors; receptor density; copper 64; copper 62; gallium 68; radioisotope decay; copper 60; clinical trials; thallium 201; nitroimidazole derivative; receptor binding; optical resolution; fluorodeoxythymidine f 18; tomography, emission-computed; tomography, emission-computed, single-photon; tumor blood flow; albumin tc 99m; annexin v tc 99m; iodine 123; oxygen 15; human; priority journal; article; oxo[3,3,9,9 tetramethyl 1 (2 nitro 1h imidazol 1 yl) 4,8 diazaundecane 2,10 dionedioximato]technetium tc 99m; promegestone; albumin i 131; apomate; bru 59 21; copper 61; copper diacetyl bis(n 4 methylthiosemicarbazone); erythrocyte tc 99m; fluoromisonidazole f 18; ga 67 transferrin; hl 91; hl 91 tc 99m; iodoquinuclidinyl benzylate i 123; xenon 133
|
